Trial Profile
A phase II, randomized trial to evaluate the efficacy and safety of pemetrexed versus docetaxel as salvage chemotherapy in patients with non small cell lung cancer who have previously failed EGFR-TKI therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Dec 2015 New trial record